MedTrace Logo

LC-Plasma for Preventing URTIs and Reducing Symptoms

NCT06827327 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 637

Last updated 2026-03-06

No results posted yet for this study

Summary

The goal of this study is to evaluate the efficacy of the LC-Plasma in preventing upper respiratory tract infections (URTIs) in healthy volunteers. Researchers will compare LC-Plasma to placebo to see if LC-Plasma prevents URTIs. Participants will take a tablet containing LC-Plasma or placebo daily for 24 weeks.

Conditions

  • Healthy Volunteer
  • URTI

Interventions

DIETARY_SUPPLEMENT

LC-Plasma

1 tablet containing 50mg LC-Plasma is taken daily for 24 weeks

OTHER

Placebo

1 tablet containing 50mg MCC is taken daily for 24 weeks

Sponsors & Collaborators

  • Kirin Holdings Company, Limited

    collaborator INDUSTRY

  • RDC Clinical Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Yusuke Ushida · Kirin Holdings Company, Limited

  • Osamu Kanauchi · Kirin Holdings Company, Limited

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-28
Primary Completion
2026-01-10
Completion
2026-01-10

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06827327 on ClinicalTrials.gov